The purpose of this study is to examine the toxicity of using allogeneic stem cell transplantation for treatment of subjects with relapsed or refractory Ewing Sarcoma (ES) and rhabdomyosarcoma. Donors will consist of either Human Leukocyte Antigen identical (HLA)or 9/10 (A, B, C, DR, DQ [A, B, C, are Class I markers for HLA and DR and DQ are Class II markers for Matching for Transplant for Donors to match with recipient]) matched related or unrelated donors. Specifically, we will examine:

Patients with an isolated local recurrence of their tumor (in the site of the primary tumor) greater than 1 year after completing therapy are excluded, as these patients could be cured with local therapy alone.

As a part of the standard of care for pre-transplant evaluation, subjects will be tested for exposure to viral agents such as hepatitis B, C, Human T-Lymphotropic Verse (HTLV)-1/2, and HIV.

Subjects testing positive for HIV may be rejected as candidates for transplantation, based on the clinical judgment of the stem cell transplant physician.

Exclusion Criteria:

Organ dysfunction: Patients who have the following levels of organ system dysfunction are not eligible:

Pulmonary: Diffusing Capacity for Carbon Monoxide (DLCO) less than 70 percent, or for patient who cannot cooperate with pulmonary function testing, O2 saturation less than 95 percent on room air.

Performance status:

Lansky performance less than 70;

Eastern Cooperative Oncology Group (ECOG) status greater than 2

Pregnant females will not be allowed to participate in this study.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01969942